NCT01358695

Brief Summary

The purpose of this study is to provide evidence of the safety, tolerance, and efficacy of ANT-1207 in the treatment of Crow's Feet.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
111

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started May 2011

Shorter than P25 for phase_2

Geographic Reach
1 country

6 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2011

Completed
19 days until next milestone

First Submitted

Initial submission to the registry

May 20, 2011

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 24, 2011

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2012

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2012

Completed
Last Updated

July 1, 2013

Status Verified

June 1, 2013

Enrollment Period

9 months

First QC Date

May 20, 2011

Last Update Submit

June 21, 2013

Conditions

Keywords

Lateral Canthal LinesCrow's Feet

Outcome Measures

Primary Outcomes (1)

  • Efficacy will be assessed by Investigator's Global Assessment Score

    Wrinkle scale with definitions of severity

    2 weeks

Secondary Outcomes (2)

  • Subject Self Assessment (SSA) scale

    2 Weeks

  • Investigator Global Assessment scale

    Week 1, 2, 4, 8, 12

Study Arms (6)

Placebo Comparator

PLACEBO COMPARATOR
Biological: ANT-1207Biological: Botulinum Toxin Type A

Dose 1

EXPERIMENTAL

Dose 1

Biological: ANT-1207Biological: Botulinum Toxin, Type ABiological: Botulinum Toxin Type A

Dose 2

EXPERIMENTAL

Dose 2

Biological: ANT-1207Biological: Botulinum Toxin, Type ABiological: Botulinum Toxin Type A

Dose 3

EXPERIMENTAL

Dose 3

Biological: ANT-1207Biological: Botulinum Toxin, Type ABiological: Botulinum Toxin Type A

Dose 4

EXPERIMENTAL

Dose 4

Biological: Botulinum Toxin, Type ABiological: Botulinum Toxin Type A

Dose 5

EXPERIMENTAL

Dose 5

Biological: Botulinum Toxin, Type ABiological: Botulinum Toxin Type A

Interventions

ANT-1207BIOLOGICAL

The interventions differ by dose of investigational product applied.

Dose 1Dose 2Dose 3Placebo Comparator

The interventions differ by dose of investigational product applied.

Dose 1Dose 2Dose 3Dose 4Dose 5Placebo Comparator

Eligibility Criteria

Age30 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • mild to moderate Crow's Feet wrinkles (IGA 2-3) at rest
  • moderate to severe Crow's Feet (IGA 3-4) on contraction
  • willingness to refrain from any product affecting skin remodeling
  • female subjects must be not pregnant and non-lactating

You may not qualify if:

  • history of peri-ocular surgery, brow lift or related procedures
  • procedures affecting the lateral canthal region in the prior 12 months
  • application of topical prescription medication to the treatment area
  • female subjects who are pregnant or are nursing a child

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (6)

Total Skin & Beauty Dermatology Center

Birmingham, Alabama, 35205, United States

Location

Baumann Cosmetic & Research Institute

Miami Beach, Florida, 33140, United States

Location

Palm Beach Esthetic Dermatology and Laser Center

West Palm Beach, Florida, 33401, United States

Location

William Coleman III, MD, APMC

Metairie, Louisiana, 70006, United States

Location

Gramercy Park Dermatology

New York, New York, 10010, United States

Location

Cary Skin Care

Cary, North Carolina, 27519, United States

Location

MeSH Terms

Interventions

Botulinum Toxins, Type A

Intervention Hierarchy (Ancestors)

Botulinum ToxinsMetalloendopeptidasesEndopeptidasesPeptide HydrolasesHydrolasesEnzymesEnzymes and CoenzymesMetalloproteasesBacterial ProteinsProteinsAmino Acids, Peptides, and ProteinsBacterial ToxinsToxins, BiologicalBiological Factors

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
FACTORIAL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 20, 2011

First Posted

May 24, 2011

Study Start

May 1, 2011

Primary Completion

February 1, 2012

Study Completion

May 1, 2012

Last Updated

July 1, 2013

Record last verified: 2013-06

Locations